Ongoing treatment(s)-Hormonal therapy Page 2 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Fulvestrant compared to aromatase inhibitors in post-menopausal women with HR+ advanced breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to look at the safety and effectiveness of fulvestrant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor-positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

Exercise, body composition and fatigue with androgen deprivation therapy

Posted by on May 22, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine whether body composition (lean and fat mass) and exercise had an effect on fatigue levels in men treated with androgen deprivation therapy. The study concluded that fat mass was associated with fatigue, and an increase in lean mass due to exercise successfully reduced fatigue. Some background Androgen...

Read More

Androgen deprivation therapy increases the risk of depression in patients with prostate cancer

Posted by on Dec 9, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine whether androgen deprivation therapy (ADT) is associated with an increased risk of depression for patients with prostate cancer. It found that there was an increased risk of depression.  Some background A main treatment option for prostate cancer is androgen deprivation therapy (ADT). This blocks...

Read More

The effect of exercise on fatigue in men receiving hormone therapy for prostate cancer

Posted by on Aug 14, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the long-term effects of different exercises on fatigue in men with prostate cancer who are receiving hormone therapy. The authors concluded that different exercises had different but comparable effects on reducing fatigue during hormone therapy. Some background Hormone therapy is a common treatment...

Read More

Is abemaciclib combined with fulvestrant effective in women with HR positive advanced breast cancer?

Posted by on Jul 15, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the effectiveness of the combination of fulvestrant (Faslodex) and abemaciclib to fulvestrant alone in patients with advanced breast cancer. This study concluded that the combination of fulvestrant and abemaciclib had improved outcomes for patients when compared to fulvestrant alone.  Some background...

Read More